POMDOCTOR LTD - ADR (POM) Fundamental Analysis & Valuation

NASDAQ:POM • US73181R1086

Current stock price

0.2807 USD
+0.03 (+12.46%)
Last:

This POM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. POM Profitability Analysis

1.1 Basic Checks

  • POM had negative earnings in the past year.
  • POM had a negative operating cash flow in the past year.
POM Yearly Net Income VS EBIT VS OCF VS FCFPOM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M

1.2 Ratios

  • The Return On Assets of POM (-454.51%) is worse than 96.00% of its industry peers.
Industry RankSector Rank
ROA -454.51%
ROE N/A
ROIC N/A
ROA(3y)-262.51%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
POM Yearly ROA, ROE, ROICPOM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • Looking at the Gross Margin, with a value of 14.62%, POM is doing worse than 64.00% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for POM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
POM Yearly Profit, Operating, Gross MarginsPOM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 20 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. POM Health Analysis

2.1 Basic Checks

  • POM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The debt/assets ratio for POM is higher compared to a year ago.
POM Yearly Shares OutstandingPOM Yearly Shares OutstandingYearly Shares Outstanding 2023 200 400 600
POM Yearly Total Debt VS Total AssetsPOM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -63.71, we must say that POM is in the distress zone and has some risk of bankruptcy.
  • POM has a worse Altman-Z score (-63.71) than 91.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -63.71
ROIC/WACCN/A
WACC4.59%
POM Yearly LT Debt VS Equity VS FCFPOM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200M -200M -400M -600M

2.3 Liquidity

  • POM has a Current Ratio of 0.21. This is a bad value and indicates that POM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • POM has a worse Current ratio (0.21) than 94.00% of its industry peers.
  • A Quick Ratio of 0.15 indicates that POM may have some problems paying its short term obligations.
  • POM's Quick ratio of 0.15 is on the low side compared to the rest of the industry. POM is outperformed by 94.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.15
POM Yearly Current Assets VS Current LiabilitesPOM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. POM Growth Analysis

3.1 Past

  • POM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.66%.
  • POM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.63%.
EPS 1Y (TTM)-1.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.3%
Revenue 1Y (TTM)13.63%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.19%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
POM Yearly Revenue VS EstimatesPOM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 100M 200M 300M

More info and screens

Find the best growth stocksShow best growing peers

0

4. POM Valuation Analysis

4.1 Price/Earnings Ratio

  • POM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
POM Price Earnings VS Forward Price EarningsPOM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
POM Per share dataPOM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. POM Dividend Analysis

5.1 Amount

  • No dividends for POM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

POM Fundamentals: All Metrics, Ratios and Statistics

POMDOCTOR LTD - ADR

NASDAQ:POM (4/7/2026, 1:29:51 PM)

0.2807

+0.03 (+12.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.69%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap33.46M
Revenue(TTM)517.03M
Net Income(TTM)-210.11M
AnalystsN/A
Price TargetN/A
Short Float %0.12%
Short Ratio1.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.6
BVpS-0.81
TBVpS-0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -454.51%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.62%
FCFM N/A
ROA(3y)-262.51%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover10.66
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.1%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.15
Altman-Z -63.71
F-Score3
WACC4.59%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.63%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.78%
OCF growth 3YN/A
OCF growth 5YN/A

POMDOCTOR LTD - ADR / POM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for POMDOCTOR LTD - ADR?

ChartMill assigns a fundamental rating of 0 / 10 to POM.


What is the valuation status of POMDOCTOR LTD - ADR (POM) stock?

ChartMill assigns a valuation rating of 0 / 10 to POMDOCTOR LTD - ADR (POM). This can be considered as Overvalued.


Can you provide the profitability details for POMDOCTOR LTD - ADR?

POMDOCTOR LTD - ADR (POM) has a profitability rating of 0 / 10.


Can you provide the financial health for POM stock?

The financial health rating of POMDOCTOR LTD - ADR (POM) is 0 / 10.